Equity Research
Independent quantitative equity research focused on identifying mispriced growth and quality companies.
SEC filing analysis, equity deep-dives, and backtest results — published when the data says something worth reading.
Research
Latest notes
Quantitative research notes on markets, factors, risk, and systematic strategies — ordered by publication date.
QXO Stock Analysis (QXO): Integration Must Fix Margins
QXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to show up in earnings. With operating margin…
Aehr Test Systems Stock Analysis (AEHR): Valuation Too Rich
Aehr Test Systems (AEHR) earns a SELL rating as its valuation far outpaces current earnings power. Revenue is falling, cash flow remains negative, and customer…
Incyte Stock Analysis (INCY): JAKAFI Cliff Looms
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable,…
Smith & Wesson (SWBI) 2026 10-K Analysis: MD&A Filing Changes
Smith & Wesson (SWBI) 2026 10-K analysis comparing MD&A changes, sales growth, tariff pressure, debt reduction, and capital allocation versus 2025.
Subscribe
Get new reports by email.
SEC filing analysis, equity deep-dives, and backtest results — delivered when published. Free, no noise.
Double opt-in · unsubscribe anytime · no advice
